Assay News and Research

RSS

Study explores role of APOBEC-mediated RNA editing in SARS-CoV-2 fitness

A new study investigated whether APOBEC proteins can directly edit the RNA sequence of SARS-CoV-2 to generate C-to-U mutations.

14 Apr 2022

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

Reaction Biology, an industry-leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

From Reaction Biology Corporation 13 Apr 2022

The molecular context and substrate profiles of human cell surface receptor tyrosine kinases

researchers discussed and identified the systemic functions and interactions of 52 active cell surface receptor tyrosine kinases, providing insights on RTK-RTK interactions and substrates, RTK-protein complexes, and signaling pathways.

13 Apr 2022

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

13 Apr 2022

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

In a recent study under consideration at Nature Portfolio Journal and posted to the Research Square* preprint server, researchers characterized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-specific cluster of differentiation 8 (CD8+) T cell responses.

12 Apr 2022

Antibody response following Omicron BA.2 infection is lower than BA.1

In a recent report posted to the medRxiv* preprint server, researchers determined immune responses generated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineage infections in prior virus-infected and naïve subjects.

12 Apr 2022

Development of 18 monoclonal antibodies against 9 SARS-CoV-2 proteins

A new study aimed to generate, characterize, and optimize Abs against SARS-CoV-2 proteins.

12 Apr 2022

Severe COVID-19 extremely rare among children

A new Journal of Infection study describes the findings in children who contracted SARS-CoV-2 infection in England.

12 Apr 2022

Injection-free dermally delivered subunit vaccine strongly neutralizes SARS-CoV-2 variants

Researchers in Australia have evaluated the vaccine candidature of HexaPro S protein subunit vaccine against SARS-CoV-2.

12 Apr 2022

Safety, reactogenicity, and immunogenicity of the BNT and half-m1273 mRNA COVID-19 vaccines given as a fourth dose booster

Researchers evaluated the immunogenicity of Pfizer’s BNT162b2 and Moderna’s mRNA-1273 vaccines offered as the fourth dose against SARS-CoV-2.

12 Apr 2022

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

In a recent study researchers evaluated the T cell responses elicited by full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein vaccine NVX-CoV2373.

12 Apr 2022

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

Researchers used cryogenic electron microscopy (cryo-EM) to determine the structure of the spike (S) protein of BA.2 sub-variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and compared them with previously determined S structures of Omicron's BA.1 sub-variant.

11 Apr 2022

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

Chromatin accessibility as an early marker of severe COVID-19

A new study explores the possible use of chromatin remodeling in predicting a severe clinical trajectory for COVID-19.

11 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

Researchers identify a potentially effective compound against COVID-19 against the SARS-CoV-2 PLpro.

10 Apr 2022

Evaluating immunogenicity after BNT162b2 booster vaccination

Researchers assessed the levels of IgG and IgA antibodies in sera samples from healthcare workers before vaccination, after the first vaccine dose, after eight months, and after a booster shot.

8 Apr 2022

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

In a new study, researchers characterized over 100 SARS-CoV-2-specific CD4+ T-cell epitopes.

8 Apr 2022

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers evaluated the immunogenicity of a third COVID-19 vaccination in antibody deficient subjects.

8 Apr 2022

Neutralization potency against the Omicron variant of naturally expressed MBC-derived IgG antibodies from vaccinated individuals

Researchers have shown how the Omicron variant of the SARS-CoV-2 successfully evaded a large fraction of antibodies derived from memory B cells, giving rise to a reduced, but incomplete immune escape.

8 Apr 2022

Assay News and Research

Study explores role of APOBEC-mediated RNA editing in SARS-CoV-2 fitness

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

The molecular context and substrate profiles of human cell surface receptor tyrosine kinases

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

Antibody response following Omicron BA.2 infection is lower than BA.1

Development of 18 monoclonal antibodies against 9 SARS-CoV-2 proteins

Severe COVID-19 extremely rare among children

Injection-free dermally delivered subunit vaccine strongly neutralizes SARS-CoV-2 variants

Safety, reactogenicity, and immunogenicity of the BNT and half-m1273 mRNA COVID-19 vaccines given as a fourth dose booster

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

Nanocell COVID-19 vaccine elicits potent neutralizing response

Chromatin accessibility as an early marker of severe COVID-19

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

Evaluating immunogenicity after BNT162b2 booster vaccination

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

Improved seroprevalence and antibody response after third COVID-19 vaccination

Neutralization potency against the Omicron variant of naturally expressed MBC-derived IgG antibodies from vaccinated individuals

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News